Mangoceuticals, Inc. (MGRX) Stock Price & Analysis
Mangoceuticals, Inc. (MGRX) fell 6.58% to USD 0.52 as of July 25, 2026 at 04:54 UTC, according to Nexqual real-time market data.
MGRX last closed at USD 0.56; the session ranged USD 0.51–0.57 on volume of 466,956 shares. Market capitalization is $8.94M, with a 52-week range of USD 0.16–2.75 (NCM). Source: Nexqual, July 25, 2026 at 04:54 UTC.
Key Statistics (as of July 25, 2026 at 04:54 UTC)
| Price | USD 0.52 |
|---|---|
| Change | ▼ 6.58% (down) |
| Previous Close | USD 0.56 |
| Open | USD 0.55 |
| Day Range | USD 0.51 – 0.57 |
| 52-Week Range | USD 0.16 – 2.75 |
| Volume | 466,956 shares |
| Market Cap | $8.94M |
| Exchange | NCM |
Technical Analysis (MGRX)
Nexqual's technical model rates MGRX "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 04:54 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 65.75 (neutral) |
| vs SMA50 | Above (USD 0.4) |
| MACD | 0.03 (positive) |
Analyst Ratings (MGRX)
Wall Street analysts rate MGRX "None", per Nexqual as of July 25, 2026 at 04:54 UTC.
| Consensus Rating | None |
|---|
Earnings (MGRX)
Source: Nexqual, July 25, 2026 at 04:54 UTC.
Financials & Fundamentals (MGRX)
| Total Revenue | $414,579 |
|---|---|
| Revenue Growth (YoY) | -37.90% |
| Gross Margin | +52.42% |
| Operating Margin | -4588.41% |
| Profit Margin | +0.00% |
| ROE | -113.90% |
| Debt / Equity | 2.18 |
| Current Ratio | 0.29 |
| Total Cash | $174,562 |
| Total Debt | $294,023 |
| Free Cash Flow | $1.43M |
Source: Nexqual, July 25, 2026 at 04:54 UTC.
Financial Health Score (MGRX)
Nexqual rates Mangoceuticals, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 04:54 UTC.
| Growth | Critical — Revenue -38% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Solid — $175K cash, no debt |
| Cash Flow | Strong — FCF $1M, 345% margin |
| Efficiency | Critical — ROE -114%, ROA -60.6% |
Ownership (MGRX)
| Insider Ownership | +10.04% |
|---|---|
| Institutional Ownership | +4.97% |
| Shares Outstanding | 17.17M |
| Float | 13.43M |
| Short % of Float | +2.50% |
Source: Nexqual, July 25, 2026 at 04:54 UTC.
Leadership (MGRX)
Mangoceuticals, Inc. is led by Jacob D. Cohen (age 46), Co-Founder, CEO & Chairman, per Nexqual as of July 25, 2026 at 04:54 UTC.
| Co-Founder, CEO & Chairman | Jacob D. Cohen (age 46) |
|---|---|
| Chief Financial Officer | Eugene M. Johnston (age 61) |
Major Backers & Investors (MGRX)
Notable institutional backers of Mangoceuticals, Inc. include Ikarian Capital, LLC, Fidelity, Jane Street Group, LLC, according to Nexqual as of July 25, 2026 at 04:54 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Ikarian Capital, LLC | 0.8% |
| Fidelity | 0.79% |
| Jane Street Group, LLC | 0.42% |
| Virtu Financial LLC | 0.36% |
| Boothbay Fund Management, LLC | 0.22% |
| Ackerman Capital Advisors, LLC | 0.2% |
| ACT Advisors, LLC. | 0.16% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.5% |
| Geode Capital | 1.13% |
| Northern Trust | 0.22% |
Source: Nexqual, July 25, 2026 at 04:54 UTC.
From Mangoceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-04-01)
Key Strengths & Strategy (as disclosed to the SEC)
- Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States.
- The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand.
- It also provides oral testosterone undecanoate to treat low testosterone in men and as a form of testosterone replacement therapy under the Prime brand; and access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations.
- In addition, the company markets and sells its products online through its website www.MangoRX.com.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SXTP | 60 Degrees Pharmaceuticals, Inc | USD 1.48 | ▼ 4.52% |
| TRNR | Interactive Strength Inc. | USD 3.17 | ▼ 0.94% |
| DRMA | Dermata Therapeutics, Inc. | USD 1.32 | ▲ 4.76% |
| CDIO | Cardio Diagnostics Holdings Inc | USD 1.55 | ▼ 7.74% |
| FRGT | Freight Technologies, Inc. | USD 3.01 | ▼ 15.45% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 04:54 UTC. This page is informational and not investment advice.